Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 10, 2022

SELL
$20.92 - $39.36 $5.68 Million - $10.7 Million
-271,589 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$31.94 - $54.82 $4.45 Million - $7.64 Million
139,289 Added 105.28%
271,589 $10 Million
Q3 2021

Nov 15, 2021

BUY
$46.0 - $73.99 $6.09 Million - $9.79 Million
132,300 New
132,300 $6.22 Million

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $343M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Nicholas Investment Partners, LP Portfolio

Follow Nicholas Investment Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Nicholas Investment Partners, LP with notifications on news.